- Last Ratings Update:11/30/2013
- Price as of 11/30/2013 :$52.11
- Net Assets:$215.6 Million
- Peer Rank:76 of 272
- Investment Rating:B+
We rate Market Vectors Pharmaceutical ETF at B+. This overall rating indicates it is among the top 10% of all closed end mutual funds in its peer group. Positive factors that influence this rating include a low price volatility and low expense structure. The fund may be considered for investors seeking an Equity Income strategy.
POSITIVES AND RISKS
New Fund off to good start in the last year. The Market Vectors Pharmaceutical ETF has returned an annual rate of 24.52% since inception. More recently, the fund has generated a total return of 34.55% in the last year, 13.57% in the last six months, and 12.59% in the last three months. How does that compare to other equity funds? In the last year, it has outperformed 84% of them for the period ending 11/30/2013. On a year to date basis, PPH has returned 33.64%.
Downside risk has been below average. PPH has a draw down risk of -5.18%, which is the largest price decline experienced since the inception of the fund. This fund has a one year standard deviation of 10.5%. This fund has had a low level of volatility in its monthly performance over the last 12 months. As of 11/30/2013, the fund was trading at a price of $52.11, which is 0.5% below its 52-week high of $52.38 and 5.0% above its 52-week low of $49.62.
Low expense ratio helps performance. On total assets of $215.60 million, PPH maintains a low expense ratio compared to its Equity Income peers of just 0.35% to cover all operating costs. Brokerage costs for the fund to buy and sell shares are not included in the expense ratio. As PPH is an exchange traded fund, it has no front end or back end load.
The Market Vectors Pharmaceutical ETF is managed by George Cao at Van Eck Associates Corporation. This fund is one of 53 Van Eck Associates Corporation exchange-traded funds launched since 5/16/2006 that we track.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
Latest Stock Upgrades/Downgrades